What is claimed:

1. An isolated ST2 antibody comprising a light chain variable domain that comprises an LCDR1 as set forth in SEQ ID NO:107; an LCDR2 sequence as set forth in SEQ ID NO:118; and an LCDR3 sequence as set forth in SEQ ID NO:129; and a heavy chain variable domain that comprises an HCDR1 as set forth in SEQ ID NO:41; an HCDR2 sequence as set forth in SEQ ID NO:52; and an HCDR3 sequence as set forth in SEQ ID NO:63.

2. The ST2 antibody of of claim 1, wherein the antibody specifically binds human ST2 with an affinity of less than or equal to 1×10^{-10} M.

3. The ST2 antibody of either of claims 1 or 2, wherein the antibody inhibits binding of human ST2 to human IL-33.

4. The ST2 antibody of any of claims 1-3, wherein the antibody reduces human IL-33-mediated ST2 signaling in human ST2-expressing cells.

5. The ST2 antibody of claim 4, wherein the antibody inhibits binding of cynomolgus monkey ST2 to cynomolgus monkey IL-33.

6 The ST2 antibody of claim 5, wherein the antibody reduces IL-33-mediated cynomolgus monkey ST2 signaling in cynomolgus monkey ST2-expressing cells.

7. The ST2 antibody of any of claims 1-6, wherein the antibody is a human antibody.

8. The ST2 antibody of claim 7 comprising a light chain and a heavy chain, wherein the light chain comprises the amino acid sequence set forth in SEQ ID:85 and the heavy chain comprises the amino acid sequence set forth in SEQ ID NO:19.

9. An isolated nucleic acid encoding an antibody of any of claims 1-8.

10. An isolated nucleic acid encoding a light chain variable domain and a heavy chain variable domain of an antibody of any of claims 1-8.

11. An expression vector comprising the isolated nucleic acid of any of claims 9-10.

12. A recombinant host cell comprising an isolated nucleic acid of any of claims 9-10 operably linked to a promoter.

23. The isolated ST2 antibody of claim 22, wherein said ST2 antibody binds an ST2 comprising amino acids 19-322 of SEQ ID NO:1 within amino acids 33-44 or 88-94 of SEQ ID NO:1 as determined by hydrogen/deuterium exchange analysis.

24. The isolated ST2 antibody of claim 23, wherein said ST2 antibody binds within amino acids 33-44 and 88-94 of SEQ ID NO:1 as determined by hydrogen/deuterium exchange analysis.

25. The ST2 antibody of claim 7, wherein the antibody comprises a light chain variable domain amino acid sequence as set forth in SEQ ID NO:96 and a heavy chain variable domain amino acid sequence as set forth in SEQ ID NO:30.

26. The use of claim 20, wherein the autoimmune or inflammatory disorder is asthma or chronic obstructive pulmonary disease.